Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography
Nikola Lübbering, Alexander Krogmann, Felix Jansen, Eicke Latz, Georg Nickenig, Sebastian Zimmer, Marc W. Merx, Marc W. Merx, Marc W. Merx · 2025
Read Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography by Nikola Lübbering, Alexander Krogmann, Felix Jansen, Eicke Latz, Georg Nickenig, Sebastian Zimmer, Marc W. Merx, Marc W. Merx, Marc W. Merx (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12747169.txt.
Description
Cholesterol crystals poking immune cells help drive artery disease, and Nikola Lübbering and co-authors tested a sugar-ring drug that might stop cells from swallowing the crystals. They drew blood from seventy-six patients undergoing heart catheter checks, isolated their monocytes, and measured crystal uptake with and without a dose of cyclodextrin, an approved drug carrier known to shuffle cholesterol.
Uptake varied widely between patients. The drug cut average uptake from about twenty percent of cells to fifteen, a clear drop. Forty patients responded strongly, nine went the other way, and patients with more inflammation or established artery disease responded least. The authors suggest the test could one day grade individual risk and monitor who benefits from such therapy.
Catalog record
| CREATOR | Nikola Lübbering, Alexander Krogmann, Felix Jansen, Eicke Latz, Georg Nickenig, Sebastian Zimmer, Marc W. Merx, Marc W. Merx, Marc W. Merx |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |